952 related articles for article (PubMed ID: 29222911)
21. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
Zhou JH; Cai JJ; She ZG; Li HL
World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
[TBL] [Abstract][Full Text] [Related]
22. [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017].
Nan YM; Fu N; Li WC; Kong LL; Yuan XW; Zhang SY; Liu LD; Lu Y; Cui LY
Zhonghua Gan Zang Bing Za Zhi; 2017 Sep; 25(9):687-694. PubMed ID: 29108191
[TBL] [Abstract][Full Text] [Related]
23. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
24. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Vilar-Gomez E; Martinez-Perez Y; Calzadilla-Bertot L; Torres-Gonzalez A; Gra-Oramas B; Gonzalez-Fabian L; Friedman SL; Diago M; Romero-Gomez M
Gastroenterology; 2015 Aug; 149(2):367-78.e5; quiz e14-5. PubMed ID: 25865049
[TBL] [Abstract][Full Text] [Related]
25. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
Agrawal S; Duseja A
Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
[TBL] [Abstract][Full Text] [Related]
26. The role of bariatric surgery in the management of nonalcoholic steatohepatitis.
Seymour KA; Abdelmalek MF
Curr Opin Gastroenterol; 2021 May; 37(3):208-215. PubMed ID: 33769376
[TBL] [Abstract][Full Text] [Related]
27. Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review.
Mann JP; Tang GY; Nobili V; Armstrong MJ
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1457-1476.e7. PubMed ID: 29857146
[TBL] [Abstract][Full Text] [Related]
28. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Golabi P; Bush H; Younossi ZM
Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
[TBL] [Abstract][Full Text] [Related]
29. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD.
Rinella ME; Tacke F; Sanyal AJ; Anstee QM;
J Hepatol; 2019 Oct; 71(4):823-833. PubMed ID: 31300231
[TBL] [Abstract][Full Text] [Related]
30. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction.
Mathews SE; Kumar RB; Shukla AP
Curr Opin Endocrinol Diabetes Obes; 2018 Oct; 25(5):315-320. PubMed ID: 30074500
[TBL] [Abstract][Full Text] [Related]
31. Nonalcoholic fatty liver disease: a systematic review.
Rinella ME
JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
[TBL] [Abstract][Full Text] [Related]
32. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
Tokushige K; Ikejima K; Ono M; Eguchi Y; Kamada Y; Itoh Y; Akuta N; Yoneda M; Iwasa M; Yoneda M; Otsuka M; Tamaki N; Kogiso T; Miwa H; Chayama K; Enomoto N; Shimosegawa T; Takehara T; Koike K
J Gastroenterol; 2021 Nov; 56(11):951-963. PubMed ID: 34533632
[TBL] [Abstract][Full Text] [Related]
33. Current Treatment Options, Including Diet, Exercise, and Medications: The Impact on Histology.
Noureddin M; Abdelmalek MF
Clin Liver Dis; 2023 May; 27(2):397-412. PubMed ID: 37024215
[TBL] [Abstract][Full Text] [Related]
34. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
[TBL] [Abstract][Full Text] [Related]
35. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.
Milic S; Mikolasevic I; Krznaric-Zrnic I; Stanic M; Poropat G; Stimac D; Vlahovic-Palcevski V; Orlic L
Drug Des Devel Ther; 2015; 9():4835-45. PubMed ID: 26316717
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
Caussy C; Reeder SB; Sirlin CB; Loomba R
Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
Gottlieb A; Mosthael W; Sowa JP; Canbay A
Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis.
Esteban JPG; Asgharpour A
Gastroenterol Clin North Am; 2020 Mar; 49(1):105-121. PubMed ID: 32033758
[TBL] [Abstract][Full Text] [Related]
39. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
40. Bariatric Surgery in NAFLD.
Chauhan M; Singh K; Thuluvath PJ
Dig Dis Sci; 2022 Feb; 67(2):408-422. PubMed ID: 34981313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
